Ipsen Sees First Mover Advantage In EU For Cabometyx In Liver Cancer

 
• By Sten Stovall

Ipsen CSO says CHMP recommendation for TKI Cabometyx should give it first mover advantage globally in liver cancer.

Liver
Ipsen's Cabometyx Gets EMA panel backing to treat hepatocellular carcinoma (HCC) • Source: Shutterstock

More from New Products

More from Scrip